HOUSTON, Texas — Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress’, the webinar will explore recent breakthroughs and ongoing challenges in the ALS landscape, including the biological drivers of disease and how advances in drug development are improving the patient experience, while underscoring where significant gaps remain. The discussion will highlight Coya’s novel immunotherapy approach for treating ALS, including the scientific rationale behind its combination therapy COYA 302 and will feature an overview of the Company’s ALSTARS Phase 2 clinical trial, including its design and enrollment information.
Fred Grossman, D.O., FAPA, President and Chief Medical Officer of Coya Therapeutics, will serve as the moderator for the webinar. He will be joined by the following participants:
- Stanley Appel, M.D. – Chairman, Scientific Advisory Board, Coya Therapeutics; Professor of Neurology, Houston Methodist
- James Berry, M.D., MPH – Director, Massachusetts General Hospital Multidisciplinary ALS Clinic
Webinar Information
Pre-registration is now open HERE
Date: February 17, 2026
Time: 3 p.m. ET / 12 p.m. PT
Attendees may ask questions via written Q&A. A recording of the event will be posted to the Coya Therapeutics website.
About COYA 302
COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS and other neurodegenerative diseases. These mechanisms may have additive or synergistic effects.
Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (Identifier: NCT07161999).
COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
For more information about Coya, please visit www.coyatherapeutics.com or follow the company on X.
Investor Contacts
David Snyder, CFO
[email protected]
astr partners
Matthew Beck
[email protected]
917-415-1750
Media Contacts
Russo Partners
David Schull
[email protected]
858-717-2310
Rachelle Babb
[email protected]
929-325-7559